Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses - Transition Therapeutics Purchase Price Allocation (Details) (Details)

v3.8.0.1
Acquisitions, Investments, and Licenses - Transition Therapeutics Purchase Price Allocation (Details) (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Aug. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]        
Goodwill $ 717,099 $ 704,603   $ 743,348
Transition Therapeutics, Inc.        
Business Acquisition [Line Items]        
Cash and cash equivalents     $ 15,878  
Goodwill     3,453  
Other assets     634  
Accounts payable and other liabilities     (1,035)  
Deferred tax liability     (1,400)  
Total purchase price     58,530  
In Process Research and Development | Transition Therapeutics, Inc.        
Business Acquisition [Line Items]        
IPR&D assets     $ 41,000